search
Back to results

Fast Allergy Sensitivity Test (FAST)

Primary Purpose

Food Allergy

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE
Sponsored by
Clinique du Trocadéro
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Food Allergy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients over 18 years old
  • Diagnosis of irritable bowel syndrome according to the ROME IV classification
  • Negative blood test: determination of IgE; anti-transglutaminase IgA assay (celiac disease)
  • Symptoms potentially related to a food allergy
  • Sufficient cooperation and understanding to comply with the requirements of the study with a post-Cellvizio medical examination at 2 weeks, 2 months and 6 months

Exclusion Criteria:

  • Patients under 18
  • Patient benefiting from a legal protection measure (curatorship, guardianship, etc.)
  • Pregnant or breastfeeding woman
  • Known allergy to fluorescein
  • Digestive cancer (stomach cancer colon rectal cancer)

Sites / Locations

  • clinique du Trocadero

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

PATIENT WITH Irritable Bowel Syndrome

Arm Description

2.5 ml of 10% fluorescein (SERB) will be administered to the patient intravenously. after the fluorescein injection. A first food allergen will be applied to the duodenal mucosa starting with the most distal part of the duodenum. After 2 minutes following the application of the allergen, observation using the endomicroscopy system can begin by applying the GastroFlex ™ UHD probe to the duodenal mucosa where the allergen has been projected. . Observation will last up to 3 minutes per site observed. If no reaction is observed, the same manipulation will be carried out using a new allergen. If the observed reaction is positive, the test will be stopped

Outcomes

Primary Outcome Measures

Observation, at the time of the endomicroscopy procedure, of ruptures / leaks in the mucous membranes and intercellular extravasation of plasma fluid labeled with fluorescein in the intercellular space
SCORE ROME IV
QUESTIONNARY
SCORE ROME IV
QUESTIONNARY
SCORE ROME IV
QUESTIONNARY

Secondary Outcome Measures

SCORE OBS-SSS
QUESTIONNARY
SCORE OBS-SSS
QUESTIONNARY
SCORE OBS-SSS
QUESTIONNARY
RESULT OH THE DIET
consultation

Full Information

First Posted
September 1, 2021
Last Updated
September 26, 2023
Sponsor
Clinique du Trocadéro
search

1. Study Identification

Unique Protocol Identification Number
NCT05072665
Brief Title
Fast Allergy Sensitivity Test
Acronym
FAST
Official Title
EFFECT OF FOOD ALLERGENS ON DUODENAL MUCOSAUS BY CONFOCAL ENDOSCOPIC IMAGING Cellvizio
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
September 1, 2021 (Actual)
Primary Completion Date
April 1, 2023 (Actual)
Study Completion Date
May 4, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Clinique du Trocadéro

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Irritable Bowel Syndrome (IBS), or functional colopathy, is a chronic disease that affects 10% to 20% of the world's population.This syndrome is characterized by chronic abdominal pain or discomfort as well as a change in bowel habits (constipation or diarrhea) in the absence of structural or metabolic abnormalities (e.g. celiac disease, Crohn's disease). These symptoms have an impact on the quality of life of these patients who must therefore integrate the management of their disease into their daily life.IBS is subdivided into 3 subtypes according to the predominant symptom: the IBS-D subtype which groups together patients who have a predominance of diarrheal episodes, the IBS-C subtype which groups together patients who have a predominance of '' episodes of constipation and finally the IBS-M subtype which includes patients whose two symptoms mentioned above are observed without predominance
Detailed Description
In 2014, Fritscher-Ravens et al., Described for the first time the value of endomicroscopy in the diagnosis of food allergies by observing the reaction of the duodenal mucosa to food allergens in patients with IBS. They assessed the structural and functional changes that were occurring in the intestinal lining in vivo and noted the following changes at the cellular level: The layers of epithelial cells break down and are removed forming voids and inducing an immediate increase in the fluid permeability of the duodenal mucosa. As a result, the contrast agent penetrates the lumen, widening the space between the villi and changing the appearance from black to white. These changes were usually seen between 2 min and 4 min after exposure to the allergen. This procedure, called FAST (Food Allergy Sensitivity Test), has since been used routinely in certain centers in Germany. However, few studies have been published that have shown the reproducibility of these results as well as the performance of this new test. The study that the investigators propose to conduct is a prospective multicenter pilot study conducted in the Trocadero Clinic 1. Pre-test consultation The patients will first be seen by a nutritionist. During this consultation, eligible patients will be offered, in addition to endoscopy performed in current practice, the possibility of performing the FAST test during endoscopy. Up to 7 days before the operation, a questionnaire allowing the assessment of the severity of symptoms (IBS-SSS) will be provided to the patient who has agreed to participate in the study. The answers to the questionnaire will be used as a reference to assess the evolution of symptoms if a food exclusion diet were to be put in place following the procedure. Finally, two to three days before the FAST test, the patient will be asked to follow an exclusion diet and consume only hypoallergenic nutritional foods: rice, potatoes, olive oil, salt. 2 Carrying out the test Before the start of the test, a standard high-end endoscopy will be performed to look for any signs of structural mucosal abnormalities that suggest gastrointestinal disease. In the event of a mucosal abnormality observed on endoscopy, the CLE FAST procedure will be canceled. In the case of mild reflux disease, the test may be done. Prior to the first challenge, 2.5 ml of 10% fluorescein (SERB) will be administered to the patient intravenously. Before any challenge and after the fluorescein injection, to establish a comparison image, a first acquisition with the endomicroscopy system of the duodenal mucosa will be carried out on a minimum of 4 sites (approximately 20 seconds each) to verify the integrity of the mucosa. During the acquisition of the reference sequences and during all subsequent acquisitions, areas of the mucosa that show bleeding and other visible signs of inflammation will not be imaged in order to avoid false positives. Once the reference images have been acquired, a first food allergen will be applied to the duodenal mucosa starting with the most distal part of the duodenum. After 2 minutes following the application of the allergen, observation using the endomicroscopy system can begin by applying the GastroFlex ™ UHD probe to the duodenal mucosa where the allergen has been projected. . Observation will last up to 3 minutes per site observed. If no reaction is observed, the same manipulation will be carried out using a new allergen. If the observed reaction is positive, the test will be stopped. The test can be performed using up to 5 different allergens as long as the total time after fluorescein injection does not exceed 30min.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Food Allergy

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PATIENT WITH Irritable Bowel Syndrome
Arm Type
Experimental
Arm Description
2.5 ml of 10% fluorescein (SERB) will be administered to the patient intravenously. after the fluorescein injection. A first food allergen will be applied to the duodenal mucosa starting with the most distal part of the duodenum. After 2 minutes following the application of the allergen, observation using the endomicroscopy system can begin by applying the GastroFlex ™ UHD probe to the duodenal mucosa where the allergen has been projected. . Observation will last up to 3 minutes per site observed. If no reaction is observed, the same manipulation will be carried out using a new allergen. If the observed reaction is positive, the test will be stopped
Intervention Type
Device
Intervention Name(s)
HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE
Intervention Description
HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE
Primary Outcome Measure Information:
Title
Observation, at the time of the endomicroscopy procedure, of ruptures / leaks in the mucous membranes and intercellular extravasation of plasma fluid labeled with fluorescein in the intercellular space
Time Frame
day 1
Title
SCORE ROME IV
Description
QUESTIONNARY
Time Frame
DAYS 28
Title
SCORE ROME IV
Description
QUESTIONNARY
Time Frame
2 months
Title
SCORE ROME IV
Description
QUESTIONNARY
Time Frame
6 months
Secondary Outcome Measure Information:
Title
SCORE OBS-SSS
Description
QUESTIONNARY
Time Frame
days 28
Title
SCORE OBS-SSS
Description
QUESTIONNARY
Time Frame
2months
Title
SCORE OBS-SSS
Description
QUESTIONNARY
Time Frame
6 months
Title
RESULT OH THE DIET
Description
consultation
Time Frame
6 MONTHS

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients over 18 years old Diagnosis of irritable bowel syndrome according to the ROME IV classification Negative blood test: determination of IgE; anti-transglutaminase IgA assay (celiac disease) Symptoms potentially related to a food allergy Sufficient cooperation and understanding to comply with the requirements of the study with a post-Cellvizio medical examination at 2 weeks, 2 months and 6 months Exclusion Criteria: Patients under 18 Patient benefiting from a legal protection measure (curatorship, guardianship, etc.) Pregnant or breastfeeding woman Known allergy to fluorescein Digestive cancer (stomach cancer colon rectal cancer)
Facility Information:
Facility Name
clinique du Trocadero
City
Paris
ZIP/Postal Code
75016
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Fast Allergy Sensitivity Test

We'll reach out to this number within 24 hrs